Canntab Therapeutics Limited
CTABF
$0.00
$0.000.00%
OTC PK
| 02/28/2023 | 11/30/2022 | 08/31/2022 | 05/31/2022 | 02/28/2022 | |
|---|---|---|---|---|---|
| Revenue | -16.40K | 13.00K | 29.90K | 31.10K | 38.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -16.40K | 13.00K | 29.90K | 31.10K | 38.10K |
| Cost of Revenue | -12.80K | 68.40K | 9.30K | 867.30K | 20.00K |
| Gross Profit | -3.60K | -55.30K | 20.50K | -836.20K | 18.20K |
| SG&A Expenses | 64.70K | 229.60K | 327.20K | 509.90K | 499.80K |
| Depreciation & Amortization | 67.80K | 127.40K | 107.80K | 148.40K | 85.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 120.20K | 438.80K | 454.40K | 1.57M | 669.40K |
| Operating Income | -136.60K | -425.80K | -424.60K | -1.54M | -631.20K |
| Income Before Tax | -305.90K | -764.60K | -362.90K | -1.14M | -329.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -305.90K | -764.60K | -362.90K | -1.14M | -329.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -305.90K | -764.60K | -362.90K | -1.14M | -329.10K |
| EBIT | -136.60K | -425.80K | -424.60K | -1.54M | -631.20K |
| EBITDA | -68.80K | -298.40K | -316.80K | -1.51M | -545.40K |
| EPS Basic | -0.01 | -0.02 | -0.01 | -0.03 | -0.01 |
| Normalized Basic EPS | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | -0.02 | -0.01 | -0.03 | -0.01 |
| Normalized Diluted EPS | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 38.91M | 38.91M | 38.91M | 38.83M | 37.74M |
| Average Diluted Shares Outstanding | 38.91M | 38.91M | 38.91M | 38.83M | 37.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |